A Phase III Randomized Study of TACE Plus an Oral Triple-Agent Cocktail Versus TACE Plus First-Line Targeted Immunotherapy in Unresectable Hepatocellular Carcinoma

Inclusion Criteria: * Age ≥ 18 years at the time of enrollment. * Diagnosis of hepatocellular carcinoma (HCC) established according to the Chinese National Liver Cancer (CNLC) guidelines, based on imaging findings and/or histopathological confirmation. * Not eligible for curative treatment, including surgical resection, local ablation, or liver transplantation. * No prior treatment for HCC, including any locoregional or systemic anticancer therapies. * Child-Pugh liver function class A or B 7. Exclusion Criteria: * Participants who had another previous or current malignant tumor, except for early-stage cancer with low risk of recurrence or a malignant tumor curatively treated \>5 years prior to enrolment with no recurrence * Participants who have severe allergy to iodine, and unable to receive TACE * Participants who have undergone a liver transplant or allogeneic bone marrow transplantation, or those who are in the waiting list for liver or bone marrow transplantation * Participants who had congenital or acquired immune deficiency, such as HIV infection * Participants who had a history of gastrointestinal bleeding within 6 months prior to randomization or a definite tendency of gastrointestinal bleeding * Participants who had undergone arterial thromboembolism within 6 months prior to randomization or a definite tendency of gastrointestinal bleeding, such as cerebrovascular accident, ≥ CTCAE grade 3 deep vein thrombosis and pulmonary embolism